FDA Commissioner Defends Agency Drug Approval Decisions
On May 5, 2026, the US Food and Drug Administration commissioner publicly defended the agency’s drug approval decisions, responding to criticism from the pharmaceutical industry and some members of Congress.
The Controversy
Several pharmaceutical companies have expressed dissatisfaction with the FDA’s approval pace and standards, arguing the agency has been overly cautious on certain medications. Some lawmakers have also raised concerns.
Commissioner Response
The FDA commissioner emphasized that approval standards will not be lowered under political or commercial pressure, and that protecting public health remains the agency’s top priority. The agency will continue to base approval decisions on scientific evidence.